Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Initiative Health welcomes Life Sciences by Stickyeyes

Initiative Health launched as a division of media agency Initiative in June 2021

- PMLiVE

Who cares… about great healthcare creative?

Prestigious awards for healthcare communications tend to be dominated by the big network agencies and their offshoots. And the work deserves the wins. Imaginative, innovative, powerful, arresting – it’s all...

11 London

- PMLiVE

COVID-19 vaccine protection wanes over time, backing up the need for boosters

While both Pfizer/BioNTech and AstraZeneca’s vaccines offer good protection, a new UK study shows the protection reduces over time and the UK's booster campaign is likely to begin in September

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery

Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve...

Impetus Digital

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

US health leaders greenlight COVID-19 booster shots for “all Americans”

In light of “very clear” evidence that protection from COVID-19 vaccines declines over time, the US will start offering boosters shots from September

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

US health leaders greenlight COVID-19 booster shots for “all Americans”

In light of “very clear” evidence that protection from COVID-19 vaccines declines over time, the US will start offering boosters shots from September

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links